Local, Multicenter, Non-interventional, Ambispective Study in Severe Hemophilia A Patients on Standard and PK-tailored Prophylaxis With Octocog Alfa (Advate®) in the Russian Federation
Latest Information Update: 13 Jul 2023
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Acronyms HAPKIDO
- Sponsors Takeda
- 10 Jul 2023 Status changed from active, no longer recruiting to completed.
- 12 Sep 2022 Planned number of patients changed from 170 to 94.
- 12 Sep 2022 Status changed from recruiting to active, no longer recruiting.